Nigel Richardson, PhDSenior Director CMC Analytical, Product Development & Supply, MST, R&D at GlaxoSmithKline
Nigel Richardson is a senior director in the CMC Analytical Division at GSK. He was awarded a PhD in synthetic organic chemistry from Exeter University. After nine years with Dow as a research analyst he moved to GSK as an analytical Team Leader within the Chemical Development division based in Stevenage, UK. Within GSK Dr Richardson has led the analytical activities from Phase I to commercialisation for Tykerb (breast cancer medicine) and led GSK’s oligonucleotide therapy for Duchenne Muscular Dystrophy into the final stages of development and regulatory submission. He has worked as chemistry lead in a team focused on oligonucleotide delivery. In his most recent position he had responsibility for a department focused on new analytical technology evaluation and deployment, PAT, chromatography platforms, LIMS/CDS systems and analytical automation.